Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
3.77 ^USD	+1.07%		-5.99%	-19.27%

06/06	Zura Bio Limited Announces Formation of a Scientific Advisory Board	CI
03/06	Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	CI

Zura Bio Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 05:01 pm IST

Zura Bio Limited reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 34.03 million compared to USD 0.925 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 9.54 a year ago.
For the six months, net loss was USD 43.62 million compared to USD 8.74 million a year ago. Basic loss per share from continuing operations was USD 2.88 compared to USD 162.3 a year ago.

Latest news about Zura Bio Limited

Zura Bio Limited Announces Formation of a Scientific Advisory Board	06/06	CI
Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	03/06	CI
Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing	23/05	MT
Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	10/05	MT
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Zura Bio Limited announced that it has received $112.4935 million in funding from a group of investors	06/05	CI
Piper Sandler Starts Zura Bio With Overweight Rating, $26 Price Target	03/05	MT
Zura Bio Insider Bought Shares Worth $499,999, According to a Recent SEC Filing	25/04	MT
Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing	25/04	MT
Zura Bio Expects To Raise About $112.5 Million in Gross Proceeds From Oversubscribed Private Placement	18/04	MT
Zura Bio Limited announced that it expects to receive $112.4935 million in funding from a group of investors	18/04	CI
Sector Update: Health Care Stocks Softer Monday Afternoon	08/04	MT
Zura Bio Shares Rise After Robert Lisicki Assumes CEO Role	08/04	MT
Oppenheimer Adjusts Zura Bio Price Target to $16 From $17, Maintains Outperform Rating	01/04	MT
Zura Bio Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Zura Bio Limited Appoints Announces Chief Executive Officer Changes	28/03	CI
Zura Bio Limited Appoints Lisicki as A Director of the Board	28/03	CI
Zura Bio Limited Announces Executive Appointments	08/01	CI
Zura Bio Insider Sold Shares Worth $8,000,000, According to a Recent SEC Filing	15/12	MT
Zura Bio Limited Appoints Kiran Nistala as Executive Vice President	07/12	CI
Zura Bio Announces Two Immunology Abstracts Presented At the World Allergy Congress in Bangkok	04/12	CI
Zura Bio Limited Announces Board Changes	14/11	CI
Zura Bio Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Ladenburg Thalmann Starts Zura Bio With Buy Rating, $10 Price Target	10/23/10	MT
Zura Bio Limited Appoints Parvinder Thiara to the Board	03/23/03	CI

Chart Zura Bio Limited

Duration

Period

More charts

Company Profile

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Sector

Biotechnology & Medical Research

Calendar

24/06/2024 - Oppenheimer Novel Targets in Immunology Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.77 USD

Average target price

17.8 USD

Spread / Average Target

+372.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZURA BIO LIMITED	-19.27%	235M
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs